- Dexcom unveils new report on Type 2 Diabetes management, emphasizing the impact of continuous glucose monitoring (CGM).
- Majority of U.S. healthcare professionals believe CGM will surpass advancements in diabetes medications in managing Type 2.
- Clinical data presented by Dexcom highlights the significant benefits of CGM at the ADA 2025 conference.
DexCom, Inc. (DXCM, Financial), a leader in glucose biosensing technologies, has released its latest "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" just ahead of the American Diabetes Association's 85th Scientific Sessions in Chicago. This new report reveals that a majority of surveyed healthcare professionals (HCPs) believe that continuous glucose monitoring (CGM) could have a more substantial impact on Type 2 diabetes management than recent advancements in diabetes medications.
The report, which surveyed over 400 healthcare professionals and individuals with Type 2 diabetes across the U.S., underscores the growing consensus among U.S. HCPs regarding the efficacy of CGM. According to the findings, 96% of healthcare providers agree that CGM should be the standard of care for individuals using multiple daily insulin injections, and 94% support its use for those on basal insulin. Moreover, the report indicates unanimous support (100%) among surveyed HCPs for the use of CGM in combination with GLP-1 or SGLT2 medications.
At the ADA conference, Dexcom will present additional clinical data supporting CGM's benefits for Type 2 diabetes patients. Notable findings include reduced mortality risk among insulin-using individuals and decreased diabetes-related distress and improved self-management in non-insulin users as a result of CGM use. These outcomes advocate the early adoption of CGM for improved diabetes management through personalized care.
Lance Bass, a Dexcom Warrior and advocate diagnosed with Latent Autoimmune Diabetes in Adults (LADA), will share his personal experiences with CGM during a panel at the ADA. His participation highlights the practical impacts of CGM in reducing reliance on traditional fingersticks.
Dexcom's comprehensive report and upcoming presentations at the ADA aim to highlight the crucial role of CGM in the future of diabetes care, promoting a broader understanding and adoption of this technology to improve patient outcomes.
